Beiske A G, Naess H, Aarseth J H, Andersen O, Elovaara I, Farkkila M, Hansen H J, Mellgren S I, Sandberg-Wollheim M, Sorensen P S, Myhr K M
Department of Neurology, University Hospital of Akershus, Lørenskog, Norway.
Mult Scler. 2007 Apr;13(3):386-92. doi: 10.1177/13524585070130030101.
Common disability scales in multiple sclerosis (MS) are often weighted towards physical disability. Non-motor symptoms such as depression, fatigue and pain substantially influence wellbeing in MS. Health-related quality of life (HRQoL) measures the broader impact of MS and might indicate less obvious disease burdens. We analysed HRQoL, using the Nottingham Health Profile Part I (NHP-I), among 345 secondary progressive MS (SPMS) patients participating in a randomized trial of interferon-beta1a (IFN-beta1a), 22 mug subcutaneously weekly, or matching placebo. The results did not reveal any beneficial effect of IFN-beta1a in any outcome measure. NHP-I sub- and sum scores were compared for 217 population controls and correlated with demographic and clinical disease variables. SPMS patients had lower NHP-I sum and all subscores than the controls. Patients experiencing disease progression reported worse NHP-I sum scores. Increased fatigue, Expanded Disability Status Scale (EDSS) and Arm Index scores were independently associated with reduction in several NHP-I subscores. SPMS patients had significantly lower HRQoL than controls and physical disability (EDSS and Arm Index), disease progression and fatigue strongly influenced this. MS.
多发性硬化症(MS)中常见的残疾评定量表通常侧重于身体残疾。诸如抑郁、疲劳和疼痛等非运动症状会对MS患者的健康状况产生重大影响。健康相关生活质量(HRQoL)衡量MS的更广泛影响,可能表明不太明显的疾病负担。我们使用诺丁汉健康概况第一部分(NHP-I)对345例参与干扰素-β1a(IFN-β1a)随机试验的继发进展型MS(SPMS)患者进行了HRQoL分析,这些患者每周皮下注射22μg IFN-β1a或匹配的安慰剂。结果未显示IFN-β1a在任何结局指标上有任何有益效果。对217名人群对照的NHP-I子分数和总分进行了比较,并与人口统计学和临床疾病变量相关联。SPMS患者的NHP-I总分和所有子分数均低于对照组。经历疾病进展的患者报告的NHP-I总分更差。疲劳增加、扩展残疾状态量表(EDSS)和手臂指数评分与几个NHP-I子分数的降低独立相关。SPMS患者的HRQoL显著低于对照组,身体残疾(EDSS和手臂指数)、疾病进展和疲劳对此有强烈影响。MS。